Last reviewed · How we verify
Chlorhexidine 0.5%
At a glance
| Generic name | Chlorhexidine 0.5% |
|---|---|
| Sponsor | Freya Biosciences ApS |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial (PHASE2)
- Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle (PHASE2)
- Intrathecal MoRphine Versus Transabdominal Plane Block (TAP) Block for AnalGesic Management in Elective Caesarean Section (PHASE4)
- Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction (PHASE3)
- A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis (PHASE1, PHASE2)
- Central Venous Catheter vs Midline in Difficulty Access Patient - Pilot Trial (NA)
- Probiotics to Actively Counter Ventilator Associated Pneumonia (PROACT) (NA)
- Advanced Dressings for CVC Infection Prevention in PICU (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chlorhexidine 0.5% CI brief — competitive landscape report
- Chlorhexidine 0.5% updates RSS · CI watch RSS
- Freya Biosciences ApS portfolio CI